Are you Dr. Lee?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 25 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
451 N Texas Ave
Webster, TX 77598Phone+1 281-333-2288Fax+1 281-335-4605
Summary
- Dr. Patricia Lee, MD is a dermatologist in Webster, Texas. She is currently licensed to practice medicine in Texas and Alabama. She is affiliated with Houston Methodist Clear Lake Hospital, HCA Houston Healthcare Clear Lake, and St. Luke's Health - Baylor St. Luke's Medical Center.
Education & Training
University of Alabama Medical CenterFellowship, Dermatopathology, 1985 - 1987
University of Texas Health Science Center at HoustonResidency, Pathology-Anatomic and Clinical, 1981 - 1985
McGovern Medical School at UTHealthClass of 1981
Certifications & Licensure
TX State Medical License 1985 - 2026
AL State Medical License 1985 - 1991- American Board of Pathology Anatomic Pathology
Clinical Trials
- A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Start of enrollment: 2013 Nov 01
- Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine Start of enrollment: 2014 Jul 01
- A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
Publications & Presentations
PubMed
- 20 citationsSpesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, plac...Robert Bissonnette, William Abramovits, Étienne Saint-Cyr Proulx, Patricia Lee, Emma Guttman-Yassky
Journal of the European Academy of Dermatology and Venereology. 2023-03-01 - 6 citationsEfficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque...Andrew Blauvelt, Kenneth B. Gordon, Patricia C. Lee, Jerry Bagel, Howard Sofen
The Journal of Dermatological Treatment. 2021-05-05 - 4 citationsEfficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse...Wendy Cantrell, P. Lee, Alan M. Mendelsohn, Stephen J. Rozzo, Wilson Liao
Journal of the European Academy of Dermatology and Venereology. 2021-02-12
